JP2015505959A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505959A5
JP2015505959A5 JP2014545002A JP2014545002A JP2015505959A5 JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5 JP 2014545002 A JP2014545002 A JP 2014545002A JP 2014545002 A JP2014545002 A JP 2014545002A JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5
Authority
JP
Japan
Prior art keywords
subject
cancer
inhibitor
group
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014545002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068005 external-priority patent/WO2013086031A1/en
Publication of JP2015505959A publication Critical patent/JP2015505959A/ja
Publication of JP2015505959A5 publication Critical patent/JP2015505959A5/ja
Pending legal-status Critical Current

Links

JP2014545002A 2011-12-05 2012-12-05 癌を有する患者に治療を選択する方法 Pending JP2015505959A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161567085P 2011-12-05 2011-12-05
US61/567,085 2011-12-05
US201261728748P 2012-11-20 2012-11-20
US61/728,748 2012-11-20
PCT/US2012/068005 WO2013086031A1 (en) 2011-12-05 2012-12-05 Method of therapy selection for patients with cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017191195A Division JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法

Publications (2)

Publication Number Publication Date
JP2015505959A JP2015505959A (ja) 2015-02-26
JP2015505959A5 true JP2015505959A5 (https=) 2016-01-28

Family

ID=48574842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014545002A Pending JP2015505959A (ja) 2011-12-05 2012-12-05 癌を有する患者に治療を選択する方法
JP2017191195A Pending JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法
JP2019182229A Pending JP2020024210A (ja) 2011-12-05 2019-10-02 癌を有する患者に治療を選択する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017191195A Pending JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法
JP2019182229A Pending JP2020024210A (ja) 2011-12-05 2019-10-02 癌を有する患者に治療を選択する方法

Country Status (4)

Country Link
US (1) US20140273006A1 (https=)
EP (1) EP2788752B1 (https=)
JP (3) JP2015505959A (https=)
WO (1) WO2013086031A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015127037A (ru) * 2012-12-07 2017-01-11 Дзе Дженерал Хоспитал Корпорейшн Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2975829A1 (en) * 2014-02-20 2015-09-03 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
CA2955141A1 (en) * 2014-07-23 2016-01-28 Ontario Institute For Cancer Research Systems, devices and methods for constructing and using a biomarker
DK3230736T3 (da) * 2014-12-12 2020-06-08 Celcuity Inc Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
CN113552350B (zh) * 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
HK1249866A1 (zh) * 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
US10724071B2 (en) 2015-10-14 2020-07-28 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
US20180117029A1 (en) * 2016-11-03 2018-05-03 Beth Israel Deaconess Medical Center, Inc. Targeting Metabolic Vulnerability in Triple-Negative Breast Cancer
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
CN113684275B (zh) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
WO2020081956A1 (en) * 2018-10-18 2020-04-23 Medimmune, Llc Methods for determining treatment for cancer patients
KR102267593B1 (ko) * 2018-10-19 2021-06-21 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
CN111888487B (zh) * 2020-09-04 2022-05-17 山西医科大学 肿瘤靶向型光声成像引导多阶段治疗纳米探针及制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
AU2005265186A1 (en) * 2004-06-21 2006-01-26 Exelixis, Inc. PFKs as modifiers of the IGFR pathway and methods of use
DK2064549T3 (da) 2006-09-21 2013-02-04 Nestec Sa Antistof-baserede arrays til detektion af flere signaltransducere i sjældne cirkulerende celler
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
CA2711843C (en) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
NZ617520A (en) * 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
JP5718319B2 (ja) 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
AU2010273319B2 (en) * 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
MX337666B (es) 2009-10-20 2016-03-14 Nestec Sa Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
CN102822676B (zh) * 2010-01-12 2015-02-18 雀巢产品技术援助有限公司 用于预测三阴性乳腺癌对疗法的应答的方法
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
EP2656077A1 (en) * 2010-12-23 2013-10-30 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
WO2012119113A2 (en) * 2011-03-02 2012-09-07 Nestec Sa Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures

Similar Documents

Publication Publication Date Title
JP2015505959A5 (https=)
Cohen Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Leto et al. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
EA201200025A1 (ru) Биомаркеры и способы определения эффективности анти-egfr антител для лечения злокачественного новообразования
RU2012134390A (ru) Способы предсказания ответа трижды негативного рака молочной железы на терапию
RU2017125053A (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
Skoura et al. Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non–small-cell lung cancer
RU2012109556A (ru) Биологические маркеры для мониторирования ответа пациента на антагонисты vegf
Machiels et al. Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
Bencsikova et al. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Peng et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis
Peták et al. Integrating molecular diagnostics into anticancer drug discovery
JP2014533960A5 (https=)
RU2013148768A (ru) Способы предсказания и улучшения выживаемости пациентов с раком желудка
Milella et al. EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy
Hatch et al. Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Dziadziuszko et al. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
Sauvageot et al. Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non–small cell lung cancers
JP2017529852A5 (https=)
Krause et al. Effective control of recalcitrant pruritus by bevacizumab: a possible role for vascular endothelial growth factor in chronic itch?
Sudhindra et al. Biomarkers, prediction, and prognosis in non–small-cell lung cancer: a platform for personalized treatment
RU2015140573A (ru) Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
Baselga et al. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788
Song et al. Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib
US10640830B2 (en) Drug selection for non-small cell lung cancer therapy